Diabetic Retinopathy

Diabetic retinopathy (DR) is a microvascular complication of diabetes mellitus characterized by progressive damage to the retinal capillary bed, leading to vision loss if untreated. It represents the leading cause of blindness in working-age adults in developed nations and affects approximately 1 in 3 diabetic patients globally. The prevalence increases significantly with disease duration (affecting ~25% of type 1 diabetics after 5 years and ~40% after 20 years) and correlates strongly with glycemic control and hypertension severity. For board examination purposes, DR serves as both a marker of systemic diabetic microvascular disease and a clinical target for intensive risk factor modification; recognizing its stages is essential for determining appropriate ophthalmology referral timing and understanding the rationale for tight glucose control in diabetes management.

The development of diabetic retinopathy involves multiple interconnected pathways triggered by chronic hyperglycemia in the retinal microcirculation:

The fundamental mechanism begins with hyperglycemia causing increased intracellular glucose in retinal capillary endothelial cells that cannot regulate glucose influx (retinal cells rely on GLUT1 transporters that are insulin-independent). Excess glucose enters four major metabolic pathways: (1) the polyol pathway, where aldose reductase converts glucose to sorbitol, which accumulates because sorbitol dehydrogenase has limited capacity; sorbitol accumulation creates osmotic stress, activates protein kinase C (PKC), and generates oxidative stress through NADPH depletion; (2) the hexosamine pathway, producing UDP-N-acetylglucosamine that leads to abnormal O-linked glycosylation of proteins, altering their function; (3) advanced glycation end products (AGEs) formation through non-enzymatic glycosylation of structural proteins like collagen and basement membrane components; and (4) the diacylglycerol (DAG)/PKC pathway, where increased glucose shunts carbons toward DAG synthesis, activating PKC-β isoform. PKC activation causes increased vascular permeability, capillary occlusion, abnormal vasoreactivity, and increased expression of vascular endothelial growth factor (VEGF). These pathways create a cascade of endothelial damage characterized by loss of tight junctions, increased vascular permeability (mediated by VE-cadherin disruption), and pericyte dropout.

Pericytes are contractile cells that stabilize retinal capillaries and regulate endothelial permeability. Hyperglycemia causes selective pericyte apoptosis through multiple mechanisms: increased oxidative stress from NADPH oxidase activation and mitochondrial dysfunction; PKC activation; and loss of platelet-derived growth factor (PDGF) signaling (PDGF normally protects pericytes through PI3K/Akt pathway activation). Pericyte loss destabilizes the capillary wall, leading to microaneurysms (focal capillary outpouchings at sites of pericyte loss), increased permeability with retinal edema, and progressive capillary occlusion. This establishes the "pericyte hypothesis" central to early DR pathophysiology—pericyte degeneration precedes endothelial cell loss and appears in electron microscopy studies before clinical manifestations become apparent.

Persistent hyperglycemia generates excessive reactive oxygen species (ROS) from multiple sources: mitochondrial electron transport chain dysfunction, NADPH oxidase activation (particularly NOX-4), uncoupling of endothelial nitric oxide synthase (eNOS), and aldose reductase activity. ROS damages cellular components, inactivates the critical vasodilator nitric oxide (NO), and triggers inflammatory cascades. Nuclear factor-kappa B (NF-κB) activation occurs downstream of ROS, leading to upregulation of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8), adhesion molecules (ICAM-1, VCAM-1), and chemokines. This inflammatory milieu recruits leukocytes that adhere to capillary walls (leukostasis), producing additional ROS through NADPH oxidase and contributing to capillary occlusion. Chronic inflammation also activates retinal Müller cells and microglia, which release more VEGF and pro-inflammatory factors, perpetuating the damaging cycle.

In response to capillary occlusion and resulting retinal ischemia, hypoxia-inducible factor-1α (HIF-1α) accumulates in ischemic retinal regions. HIF-1α transcriptionally activates VEGF expression—the primary driver of pathologic neovascularization in DR. VEGF signaling through VEGF receptor-2 (VEGFR-2) on endothelial cells paradoxically increases vascular permeability while promoting sprouting angiogenesis. However, these new vessels are structurally abnormal: they lack normal pericyte coverage, have increased permeability, leak plasma proteins, and are prone to hemorrhage. Additionally, VEGF and angiopoietin imbalance favors vessel instability. The combination of ischemic retina and neovascular proliferation characterizes proliferative DR, where fibrovascular proliferation at the optic disc and along vascular arcades can eventually cause tractional retinal detachment.

The inner blood-retinal barrier (BRB) consists of retinal capillary endothelial cells connected by tight junctions (occludin, claudins, ZO-1) and is supported by the retinal pigment epithelium (outer BRB). Hyperglycemia disrupts BRB integrity through multiple mechanisms: VE-cadherin phosphorylation by Src kinase (downstream of VEGF and angiopoietin-2), claudin dysregulation, occludin internalization, and increased matrix metalloproteinase (MMP-2 and MMP-9) activity degrading tight junction proteins and basement membrane. VEGF directly increases permeability through increased expression of Src and Pyk2 kinases. Loss of tight junction integrity allows fluid and plasma proteins to accumulate in the retina, manifesting clinically as retinal edema. This is the pathophysiological basis for diabetic macular edema (DME), the most common cause of vision loss in DR.

Abnormal retinal blood flow develops through endothelial dysfunction causing increased blood viscosity, reduced blood flow velocity, and eventually capillary non-perfusion. Retinal hypoxia triggers anaerobic metabolism with lactate accumulation, further damaging vessels. Protein kinase C overactivation increases vascular tone and reduces vasodilation. Loss of autoregulation means retinal perfusion becomes directly dependent on systemic blood pressure, increasing vulnerability to ischemic injury during blood pressure fluctuations. Genetic factors and individual susceptibility also modulate progression—certain polymorphisms in VEGF, VEGFR, and aldose reductase genes predict more aggressive disease.

Diabetic retinopathy is fundamentally a complication of both type 1 and type 2 diabetes. Type 1 diabetes typically shows earlier onset of DR (appearing 3-5 years after disease onset) due to the immediate metabolic derangement, while type 2 diabetes may have asymptomatic DR at diagnosis (reflecting years of undetected hyperglycemia). The pathophysiology is identical between types, though the clinical context differs.

The strongest modifiable risk factor for DR development and progression. The Diabetes Control and Complications Trial (DCCT) demonstrated that each 1% reduction in HbA1c reduces the risk of DR development by approximately 35-40%. Conversely, HbA1c >9% is strongly associated with rapid progression. The relationship is continuous with no demonstrated glycemic threshold below which DR cannot develop, though risk increases substantially above 7-8% HbA1c.

Disease duration directly correlates with DR prevalence. Approximately 25% of type 1 diabetics develop any DR by 5 years; this increases to ~80% by 15 years. For type 2 diabetes, prevalence increases from ~20% at diagnosis (reflecting prior undetected diabetes) to ~50% by 10 years. Even with good glycemic control, longer disease duration carries inherent risk from cumulative metabolic damage.

Systemic hypertension is the second-strongest modifiable risk factor after glycemia. Hypertension accelerates DR progression by increasing capillary hydrostatic pressure, promoting leukostasis, enhancing VEGF expression, and exacerbating endothelial dysfunction. The DCCT demonstrated that each 10 mmHg reduction in mean arterial pressure reduces 3-year progression of DR by approximately 20%. Aggressive antihypertensive therapy (target BP <130/80 mmHg in most diabetics with DR) is standard.

Elevated triglycerides and low HDL cholesterol are independent risk factors for both DR development and progression to vision-threatening complications. The relationship appears mediated through increased inflammatory cytokines and oxidative stress. Lipid deposition within the retina (hard exudates) characterizes more advanced disease, and lipid-lowering with statins may reduce retinopathy progression.

Low hemoglobin reduces oxygen delivery to already-stressed retinal tissue, promoting ischemia and VEGF upregulation. Anemia is associated with more severe DR. Conversely, increased hemoglobin (as in polycythemia) thickens blood and impairs microcirculatory flow.

Pregnancy dramatically accelerates DR progression through unknown mechanisms, possibly involving increased VEGF, angiopoietin dysregulation, and placental growth factor (PlGF) changes. Preexisting DR may progress from non-proliferative to proliferative disease during pregnancy despite maintained glycemic control. Conversely, oral contraceptives and hormone replacement therapy do not significantly increase DR risk in well-controlled diabetics.

DR and diabetic nephropathy share common pathophysiology and frequently coexist. Severe renal disease increases DR severity, possibly through worsening hypertension, uremia-induced oxidative stress, and anemia. Patients with proteinuria have a higher prevalence of vision-threatening DR.

Puberty accelerates DR onset and progression in type 1 diabetes, likely through increased growth hormone and IGF-1 levels. Younger patients at diabetes onset (pediatric) paradoxically may develop more severe DR if diabetes remains poorly controlled through adolescence.

Certain genetic variants predispose to severe DR independent of glycemic control: VEGF promoter polymorphisms, VEGFR-2 variants, aldose reductase gene polymorphisms, and eNOS variants influence disease severity and anti-VEGF responsiveness.

Most patients with mild to moderate non-proliferative DR are completely asymptomatic—retinopathy is discovered only on screening funduscopy or retinal imaging. This represents a critical teaching point: DR is often advanced before causing visual symptoms, necessitating proactive screening rather than waiting for patient-reported symptoms. Even proliferative DR can be asymptomatic in early stages if central vision is spared.

Patients may describe sudden onset of dark spots, cobwebs, or "hair-like" structures moving across the visual field. Floaters in DR represent vitreous hemorrhage from bleeding neovessels—blood cells and hemoglobin in the vitreous scatter light and create shadows on the retina. The sudden onset of multiple new floaters, especially in a diabetic patient, should raise concern for neovascularization with hemorrhage and warrants urgent ophthalmology evaluation. Small hemorrhages may resolve, but large hemorrhages can cause sudden marked vision loss.

Progressive blurring occurs through multiple mechanisms: retinal edema (from BRB breakdown), refractive changes (hyperglycemia causes lens swelling through sorbitol accumulation, shifting refraction), vitreous hemorrhage opacity, or macular ischemia (reduction in perfusion to the fovea causing irreversible vision loss). Importantly, non-proliferative retinopathy without macular edema typically does not cause visual symptoms, so new blurred vision in a diabetic should prompt evaluation for DME or other complications.

Wavy or distorted appearance of straight lines indicates macular edema involving the central macula—the accumulating fluid physically distorts the photoreceptor layer and disrupts normal spatial processing by the fovea. This is more specific for DME than general blurred vision and often prompts patients to seek care.

Localized areas of vision loss correspond to retinal areas with capillary non-perfusion (ischemic retina cannot transmit visual information). In proliferative DR with substantial ischemia, patients may notice peripheral visual field constriction or central scotomas. Acute scotomas should raise concern for retinal artery occlusion (a vaso-occlusive complication).

Sudden, marked vision loss in a diabetic patient can result from: (1) vitreous hemorrhage from neovascular bleeding, (2) retinal artery occlusion from thrombosis, (3) retinal detachment (tractional in proliferative DR or rhegmatogenous if combined with other ocular pathology), or (4) acute macular ischemia. This represents an ophthalmologic emergency requiring immediate evaluation.

Early findings include microaneurysms—small red dots, typically 15-60 μm in diameter, representing focal capillary outpouchings at sites of pericyte loss. These appear as isolated red spots on the retina and are the hallmark early lesion of DR. Microaneurysms are often difficult to distinguish from dot hemorrhages (which are slightly larger and darker) but represent similar pathology. Retinal hemorrhages appear as larger red patches (larger than microaneurysms); these are classified as dot/blot hemorrhages (if small and superficial in the nerve fiber layer) or flame hemorrhages (if in the superficial retina, following nerve fiber layer anatomy). Hard exudates appear as yellow or white deposits with sharp edges, representing lipid and lipoprotein deposition in areas of previous vascular leakage—these often accumulate around areas of microaneurysms and hemorrhages, sometimes forming "circinate" patterns (circular accumulation around a central microaneurysm). Cotton-wool spots appear as white, fluffy retinal patches with ill-defined borders, representing nerve fiber layer infarcts from capillary occlusion—these indicate retinal ischemia and predict progression to proliferative DR. Venous abnormalities include venous dilation and beading (segmental dilations and constrictions of retinal veins), reflecting compensatory changes in response to capillary occlusion.

Neovascularization of the disc (NVD) appears as delicate new vessels arising from the optic disc margin, more perfuse than normal retinal vessels and often surrounded by fibrous tissue. This is the classic finding of PDR and indicates severe retinal ischemia triggering VEGF-mediated angiogenesis. Neovascularization elsewhere (NVE) describes new vessels at other retinal sites, particularly along vascular arcades. These abnormal vessels are fragile, lack proper pericyte coverage, and are prone to hemorrhage—they often bleed, causing sudden vision loss. Fibrovascular proliferations are elevated masses of new vessels combined with fibrous connective tissue; these can contract (fibroglial membranes), causing tractional retinal detachment. Preretinal hemorrhages (subhyaloid hemorrhages) appear as dark red patches in the preretinal space, often with a fluid level if recent (appearing as a blood-dark interface). These are characteristic of PDR with active neovascular bleeding.

DME may occur in isolation (without other DR features) but commonly accompanies NPDR or PDR. Fundoscopically, the macula appears thickened and may have a "honey-combed" appearance from cystic spaces of accumulated fluid. Lipid exudates concentrate in the macula, appearing as yellowish deposits. Macular thickening is best appreciated on stereoscopic examination or optical coherence tomography (OCT), where retinal thickness exceeds 250 micrometers at the foveal center. The ma

Screening is the diagnostic entry point (per the ADA Standards of Care in Diabetes and the AAO Diabetic Retinopathy Preferred Practice Pattern):